The FDA on May 20, 2021 approved OPDIVO® for patients with completely resected Esophageal or GastroEsophageal Junction (GEJ) cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy. OPDIVO® is a product of Bristol-Myers Squibb Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
